iOnctura doses first subject in Phase II uveal melanoma treatment trial
Onctura has dosed the first subject in the open-label Phase II OCULE-01 trial of oral roginolisib in individuals with rare ...
Oncology Nurse Advisor1 天
Melanoma in Adolescents and Young Adults: Declining Incidence, Rising Mortality
Melanoma in adolescents and young adults (AYAs) has distinct epidemiologic characteristics, with a declining incidence over the past 2 decades but an increasing trend in all-cause and cancer-specific ...
European Medical Journal7 天
Optimising Treatment Strategies for Advanced Melanoma
The study enrolled 64 patients with treatment-naïve metastatic melanoma between March 2017 and July 2019. Participants ...
Targeted Oncology2 天
Truong Factors Age and High-Grade Toxicity Risk Into IO Selection in Melanoma
During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma ...
PharmiWeb1 天
iOnctura commences randomized Phase II study in metastatic uveal melanoma
Onctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces it has dosed the first patient in the randomized Phase II OCULE-01 study ...